Home | All trials

[RDF data]
Trial NCT00000586

Resource URI: http://static.linkedct.org/resource/trials/NCT00000586
linkedct:brief_title Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH)
linkedct:condition <http://static.linkedct.org/resource/condition/5761>
linkedct:condition <http://static.linkedct.org/resource/condition/5803>
linkedct:condition <http://static.linkedct.org/resource/condition/943>
linkedct:criteria Men and women, ages 18 to 50, who had at least three emergency room visits or hospitalizations for sickle cell anemia during the year prior to recruitment. Patients with greater than 20 crises per year were included. A total of 295 patients had Hb ss and four had Hb SB thalassemia.
linkedct:description BACKGROUND: In spite of the fact that advances have been made in the management or prevention of some of the complications of sickle cell disease, the management of the most common complication--the painful crisis--is still unsatisfactory, and appropriate methods for its prevention are unknown. The morbidity associated with a painful crisis is much more than the suffering from pain alone. The interference with a normal lifestyle, the resulting obstacles to obtaining an education and holding a job, the risk of narcotics addiction, the cost of multiple hospitalizations, and the financial impact on the family and the individual must all be considered. Evidence from the Cooperative Study of Sickle Cell Disease (CSSCD) study showed that there is an association between multiple pain events and early death in young adults. If this association is true, then MSH has the potential to not only reduce morbidity but mortality as well. The CSSCD study has shown that over 50 percent of patients with sickle cell disease have at least one crisis per year, and a considerable number have more. These episodes are believed to occur as a result of hemoglobin S within the red cells leading to rigid, non-deformable cells which can no longer traverse the microvasculature and as a result produce obstruction with consequent pain, ischemia, and tissue necrosis. Previous approaches to the therapy of this group of disorders have included: attempts to modify the hemoglobin molecule so as to prevent polymerization; the use of vasoreactive drugs; and increasing red cell volume. All of these attempts have been abandoned either because of their inefficacy, toxicity, or impracticality. Chronic exchange transfusion programs have been of limited usefulness because of high rates of isoimmunization, iron overload, and risk of transmission of hepatitis and retroviral disease. The rationale for the present study draws its substance from the observation that patients with higher levels of fetal hemoglobin (Hb F) (particularly the Saudi Arabian group), and infants who also have high Hb F levels have fewer crises. Several myelosuppressive drugs, such as 5-azacytidine and hydroxyurea, have been shown to increase Hb F production. The work with 5-azacytidine has had to be abandoned because of the known risk of malignancy. Preliminary studies by the investigators and others have shown convincingly that Hb F levels can be increased by administering hydroxyurea to patients over a several month period without producing dangerous levels of myelosuppression. The patients have also had a rise in their red cell life span and hematocrit. Further, it has been reported that these patients had a dramatic decrease in crisis frequency. This agent is readily available to all physicians, and there is evidence that it is being used without adequate justification and, possibly, without adequate monitoring. The timing of this study is therefore critical to ensure that an adequate answer to the question of efficacy is obtained and the risk of inappropriate use minimized. DESIGN NARRATIVE: Phase I has concluded. Phase II, also concluded, was a randomized, double-blind, placebo-controlled trial. Patients in the Phase II trial were recruited from 21 clinics and randomized to receive hydroxyurea or placebo. The hydroxyurea was gradually increased from an initial dose of 15 mg/kg to the maximal level tolerated by each patient in order to maximize red blood cell hemoglobin F(Hb F) content without undue marrow suppression. Changes in Hb F production were monitored in each of the two groups by a variety of laboratory tests. The primary endpoint was a comparison of crisis rates in the treated and control groups. Painful crises were defined as pain lasting longer than four hours, requiring parenteral narcotics for relief, including chest syndrome but excluding ankle ulcer pain. Secondary endpoints included changes in pain severity and duration, psychosocial status, complications of the disease, and reasons for non-compliance with either regimen. Patients were followed for two to three years depending on when they entered the study. Because of the mutagenic nature of hydroxyurea, the use of contraception was a requirement of admission to the study. The trial was stopped early, on January 14, 1995, instead of in May 1995. The Data and Safety Monitoring Board determined that daily doses of hydroxyurea reduced the frequency of painful episodes and hospital admissions for those crises by about 50 percent. Beginning in 1996, a five year follow-up of the adult patients in MSH was initiated. The purpose was to ascertain the long-term effects of hydroxyurea in this patient population. Patients were followed annually to determine health status, quality of life, incidence of malignancies, and birth defects in their offspring. In addition, mortality rates were determined so that a comparison could be made between this cohort and the mortality data from the Cooperative Study of Sickle Cell Disease (CSSCD) adult cohort and the normal African-American population mortality data. The follow-up was conducted in three phases. Phase I or the Planning Phase in which the final protocol was developed, lasted three months. Phase II, patient entry between March 1996 and June 1996 and patient follow-up, extended from the fourth to the 48th month. Phase III, patient exit and data analysis, were carried out during the final nine months of the study. The DSMB stopped MSH Phase III early because the study showed that hydroxyurea substantially reduced the frequency of vaso-occlusive (painful) crises.
linkedct:download_date Information obtained from ClinicalTrials.gov on December 30, 2009
linkedct:eligibility_gender Both
linkedct:eligibility_healthy_volunteers No
linkedct:eligibility_maximum_age 50 Years
linkedct:eligibility_minimum_age 18 Years
linkedct:end_date June 1994
linkedct:enrollment 0 (xsd:int)
linkedct:firstreceived_date October 27, 1999
linkedct:id NCT00000586
rdfs:label Trial NCT00000586
linkedct:lastchanged_date January 26, 2009
linkedct:lead_sponsor_agency National Heart, Lung, and Blood Institute (NHLBI)
linkedct:nct_id NCT00000586
linkedct:number_of_arms 0 (xsd:int)
linkedct:number_of_groups 0 (xsd:int)
linkedct:official_title Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH)
linkedct:org_study_id 306
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/41359>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/52762>
linkedct:overall_status Completed
linkedct:oversight <http://static.linkedct.org/resource/oversight/2918>
foaf:page <http://clinicaltrials.gov/show/NCT00000586>
linkedct:phase Phase 3
linkedct:primary_completion_date June 1994
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/67938>
linkedct:reference <http://static.linkedct.org/resource/reference/16886>
linkedct:reference <http://static.linkedct.org/resource/reference/18993>
linkedct:reference <http://static.linkedct.org/resource/reference/45873>
linkedct:reference <http://static.linkedct.org/resource/reference/49650>
linkedct:reference <http://static.linkedct.org/resource/reference/51128>
linkedct:reference <http://static.linkedct.org/resource/reference/51386>
linkedct:reference <http://static.linkedct.org/resource/reference/51601>
linkedct:reference <http://static.linkedct.org/resource/reference/52366>
linkedct:reference <http://static.linkedct.org/resource/reference/53043>
linkedct:reference <http://static.linkedct.org/resource/reference/53065>
linkedct:reference <http://static.linkedct.org/resource/reference/7166>
linkedct:source National Heart, Lung, and Blood Institute (NHLBI)
linkedct:start_date January 1992
linkedct:study_design Treatment, Randomized, Double-Blind, Placebo Control
linkedct:study_type Interventional
linkedct:summary To assess the efficacy and safety of orally administered hydroxyurea in the treatment of painful crises in patients with sickle cell anemia.
rdf:type linkedct:trials
linkedct:verification_date January 2009